Target type: biologicalprocess
The process in which the muscular septum is generated and organized. The muscular septum is the lower part of the ventricular septum. [GOC:mtg_heart]
Muscular septum morphogenesis is a complex and essential process in the development of various tissues and organs. It involves the formation of specialized cell structures, known as muscular septa, which serve as physical barriers and provide structural support. The process is highly regulated and involves the coordinated action of multiple cellular and molecular mechanisms.
**1. Initiation and Signaling:**
- The process often initiates with signaling molecules, such as growth factors and transcription factors, which regulate gene expression and induce the expression of specific proteins involved in septum formation.
**2. Cell Differentiation and Migration:**
- Specific cell types, such as myoblasts or mesenchymal cells, are recruited to the site of septum formation. These cells undergo differentiation, acquiring the characteristics of muscle cells, and migrate to the appropriate location.
**3. Cytoskeletal Rearrangement:**
- The cytoskeleton of the cells undergoes significant rearrangement, enabling the cells to elongate and form elongated, spindle-shaped structures. Actin filaments play a crucial role in this process, forming contractile bundles that drive cell shape changes.
**4. Cell-Cell Adhesion and Fusion:**
- As cells migrate and elongate, they establish close contact with each other. Cell-cell adhesion molecules, such as cadherins, mediate this interaction and ensure the proper alignment of cells for septum formation.
- In some cases, cell fusion can occur, where multiple cells merge into a single multinucleated structure, contributing to the formation of the muscular septum.
**5. Extracellular Matrix Deposition:**
- The extracellular matrix, composed of proteins and other molecules, provides structural support and helps guide the formation of the septum. Specialized ECM proteins, such as laminin and collagen, are deposited in a specific pattern, influencing the shape and orientation of the septum.
**6. Maturation and Remodeling:**
- Once the septum is formed, it undergoes further maturation and remodeling. This involves the fine-tuning of cell-cell junctions, the organization of muscle fibers, and the establishment of functional units within the septum.
**7. Role in Development:**
- Muscular septa play crucial roles in a variety of developmental processes, including:
- **Organogenesis:** Separating and compartmentalizing developing organs, ensuring their proper structure and function.
- **Tissue regeneration:** Guiding the formation of new tissue during repair processes.
- **Cardiovascular development:** Forming the septa that separate chambers in the heart.
- **Muscle development:** Providing structural support and organizing muscle fibers.
**8. Regulation and Dysregulation:**
- The process of muscular septum morphogenesis is precisely regulated by a complex network of genes, signaling pathways, and mechanical forces.
- Disruptions in these regulatory mechanisms can lead to developmental defects and diseases, such as congenital heart defects or muscular dystrophies.'
"
Protein | Definition | Taxonomy |
---|---|---|
Bone morphogenetic protein 4 | A bone morphogenetic protein 4 that is encoded in the genome of human. [PRO:CNA, UniProtKB:P12644] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
dorsomorphin | dorsomorphin : A pyrazolopyrimidine that is pyrazolo[1,5-a]pyrimidine which is substituted at positions 3 and 6 by pyridin-4-yl and p-[2-(piperidin-1-yl)ethoxy]phenyl groups, respectively. It is a potent, selective, reversible, and ATP-competitive inhibitor of AMPK (AMP-activated protein kinase, EC 2.7.11.31) and a selective inhibitor of bone morphogenetic protein (BMP) signaling. dorsomorphin: an AMPK inhibitor | aromatic ether; piperidines; pyrazolopyrimidine; pyridines | bone morphogenetic protein receptor antagonist; EC 2.7.11.31 {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} inhibitor |
ldn 193189 | LDN 193189: inhibits bone morphogenetic protein signaling | pyrimidines | |
ml347 | ML347: an ALK2 inhibitor; structure in first source |